SK284865B6 - Použitie fosfolipidových komplexov oligomérnych proantokyanidov extrahovaných z Vitis vinifera na prevenciu a liečenie aterosklerotických patologických ťažkostí - Google Patents

Použitie fosfolipidových komplexov oligomérnych proantokyanidov extrahovaných z Vitis vinifera na prevenciu a liečenie aterosklerotických patologických ťažkostí Download PDF

Info

Publication number: SK284865B6
Authority: SK; Slovakia
Prior art keywords: vitis vinifera; treatment; prevention; phospholipid complexes; useful
Prior art date: 1997-12-04

Application number

SK827-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK8272000A3 (en

Inventor

Paolo Morazzoni

Ezio Bombardelli

Original Assignee

Indena S. P. A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-04

Filing date

1998-11-30

Publication date

2006-01-05

1998-11-30 Application filed by Indena S. P. A. filed Critical Indena S. P. A.

2000-11-07 Publication of SK8272000A3 publication Critical patent/SK8272000A3/sk

2006-01-05 Publication of SK284865B6 publication Critical patent/SK284865B6/sk

Links

240000006365 Vitis vinifera Species 0.000 title claims abstract description 15
235000014787 Vitis vinifera Nutrition 0.000 title claims abstract description 15
235000002532 grape seed extract Nutrition 0.000 title claims abstract description 15
150000003904 phospholipids Chemical class 0.000 title claims abstract description 12
238000011282 treatment Methods 0.000 title claims description 8
230000002265 prevention Effects 0.000 title claims description 3
229920002770 condensed tannin Polymers 0.000 title abstract description 5
230000003143 atherosclerotic effect Effects 0.000 title description 6
230000001575 pathological effect Effects 0.000 title 1
239000003814 drug Substances 0.000 claims abstract description 7
125000004403 catechin group Chemical group 0.000 claims abstract description 5
206010008118 cerebral infarction Diseases 0.000 claims abstract description 4
208000010125 myocardial infarction Diseases 0.000 claims abstract description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 3
208000026106 cerebrovascular disease Diseases 0.000 claims description 3
239000007903 gelatin capsule Substances 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000006186 oral dosage form Substances 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 4
238000011321 prophylaxis Methods 0.000 abstract description 2
230000002107 myocardial effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
239000000284 extract Substances 0.000 description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
235000005911 diet Nutrition 0.000 description 5
230000037213 diet Effects 0.000 description 5
230000003902 lesion Effects 0.000 description 5
230000002792 vascular Effects 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000009467 reduction Effects 0.000 description 4
235000010469 Glycine max Nutrition 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
210000000702 aorta abdominal Anatomy 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010058178 Aortic occlusion Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
108010069201 VLDL Cholesterol Proteins 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000005800 cardiovascular problem Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009552 doppler ultrasonography Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000000694 effects Effects 0.000 description 1
LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
235000012734 epicatechin Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940074391 gallic acid Drugs 0.000 description 1
235000004515 gallic acid Nutrition 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
239000000178 monomer Substances 0.000 description 1
235000021590 normal diet Nutrition 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
150000008442 polyphenolic compounds Chemical class 0.000 description 1
235000013824 polyphenols Nutrition 0.000 description 1
235000021003 saturated fats Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Alternative & Traditional Medicine (AREA)
Mycology (AREA)
Microbiology (AREA)
Botany (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Organic Chemistry (AREA)
Vascular Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Solid Fuels And Fuel-Associated Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK827-2000A 1997-12-04 1998-11-30 Použitie fosfolipidových komplexov oligomérnych proantokyanidov extrahovaných z Vitis vinifera na prevenciu a liečenie aterosklerotických patologických ťažkostí SK284865B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT97MI002690A IT1296920B1 (it)	1997-12-04	1997-12-04	Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici
PCT/EP1998/007662 WO1999029331A1 (en)	1997-12-04	1998-11-30	The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents

Publications (2)

Publication Number	Publication Date
SK8272000A3 SK8272000A3 (en)	2000-11-07
SK284865B6 true SK284865B6 (sk)	2006-01-05

Family

ID=11378312

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK827-2000A SK284865B6 (sk)	1997-12-04	1998-11-30	Použitie fosfolipidových komplexov oligomérnych proantokyanidov extrahovaných z Vitis vinifera na prevenciu a liečenie aterosklerotických patologických ťažkostí

Country Status (22)

Country	Link
US (1)	US6297218B1 (cs)
EP (1)	EP1035859B1 (cs)
JP (1)	JP4456267B2 (cs)
KR (1)	KR100567867B1 (cs)
CN (1)	CN1126564C (cs)
AT (1)	ATE258802T1 (cs)
AU (1)	AU743031B2 (cs)
BR (1)	BR9805813B1 (cs)
CA (1)	CA2312795C (cs)
CZ (1)	CZ299555B6 (cs)
DE (1)	DE69821524T2 (cs)
DK (1)	DK1035859T3 (cs)
ES (1)	ES2214755T3 (cs)
HU (1)	HU228109B1 (cs)
IT (1)	IT1296920B1 (cs)
NO (1)	NO324796B1 (cs)
PL (1)	PL191023B1 (cs)
PT (1)	PT1035859E (cs)
RU (1)	RU2207866C2 (cs)
SI (1)	SI1035859T1 (cs)
SK (1)	SK284865B6 (cs)
WO (1)	WO1999029331A1 (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1304183B1 (it) *	1998-12-18	2001-03-08	Indena Spa	Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici.
JP2001122791A (ja)	1999-10-20	2001-05-08	Boehringer Ingelheim Internatl Gmbh	下肢の慢性静脈不全の軽減および予防のための赤色ブドウ樹葉の水性抽出物よりなる食事補強剤
JP4574788B2 (ja)	2000-03-24	2010-11-04	協和発酵バイオ株式会社	プロアントシアニジン含有組成物
IT1320080B1 (it) *	2000-10-25	2003-11-18	Giuliani Spa	Composizione per uso farmaceutico o dietetico.
FR2836337B1 (fr) *	2002-02-28	2004-11-19	Bio Serae Laboratoires	Utilisation des polymeres procyanidoliques a titre d'agents inhibuteurs des alpha-amylases et application dans des compositions a visees dietetiques
AU2003298180B2 (en) *	2002-12-31	2010-01-21	Boehringer Ingelheim International Gmbh	Film coated tablet comprising an extract of red vine leaves
US20040151769A1 (en) *	2002-12-31	2004-08-05	Boehringer Ingelheim International Gmbh	Film coated tablet containing an extract of red vine leaves
ITMI20031313A1 (it) *	2003-06-27	2004-12-28	Indena Spa	Associazioni di agenti vasoprotettori e formulazioni che li contengono.
EP1550450A1 (en) *	2003-12-29	2005-07-06	Boehringer Ingelheim International GmbH	Composition comprising an aqueous extract of red vine leaves and a blood circulating-improving agent for the treatment of chronic venous insufficiencies
JP2007523110A (ja)	2004-02-19	2007-08-16	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	赤ブドウ葉の抽出物および抗炎症剤を含む、慢性静脈疾患を治療するための組成物
US20060088617A1 (en) *	2004-10-23	2006-04-27	Mccurry James M	Chocolate composition and method for benefiting the cardiovascular system
AT501682A1 (de)	2005-01-14	2006-10-15	Hermine Dr Engl	Verfahren zur herstellung einer wirkstoffmischung
EP1837030A1 (en)	2006-03-09	2007-09-26	INDENA S.p.A.	Phospholipid complexes of curcumin having improved bioavailability
RU2314118C1 (ru) *	2006-08-08	2008-01-10	Майя Отаровна Везиришвили	Способ получения экстракта из кистей соплодий винограда культурного, обладающего антиоксидантной активностью
EP2829277A1 (en)	2013-07-26	2015-01-28	Natac Biotech, S.L.	Use of a-type proanthocyanidins in treating a mineralocorticoid receptor related disease
AU2018360383A1 (en)	2017-11-02	2020-05-21	Natureceuticals Sdn. Bhd.	Extract of orthosiphon stamineus, formulations, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2092743A1 (en) *	1970-06-15	1972-01-28	Aquitaine Invest Pharma	Complete extraction of total flavanol gomers from plats -peripheral - venous activity
GB1541469A (en) *	1976-12-01	1979-02-28	Inverni Della Beffa Spa	Method of obtaining flavonolic oligomers
IT1201151B (it) *	1987-01-14	1989-01-27	Indena Spa	Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
US5484594A (en) *	1988-06-28	1996-01-16	Tecnofarmaci S.P.A.	Process for preparing grapeseed extracts enriched in procyanidol oligomers
FI955691A7 (fi)	1994-11-28	1996-05-29	Suntory Ltd	Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet

1997
- 1997-12-04 IT IT97MI002690A patent/IT1296920B1/it active IP Right Grant
1998
- 1998-11-30 CZ CZ20002038A patent/CZ299555B6/cs not_active IP Right Cessation
- 1998-11-30 DE DE69821524T patent/DE69821524T2/de not_active Expired - Lifetime
- 1998-11-30 CN CN98811768A patent/CN1126564C/zh not_active Expired - Fee Related
- 1998-11-30 RU RU2000114174/14A patent/RU2207866C2/ru not_active IP Right Cessation
- 1998-11-30 HU HU0100522A patent/HU228109B1/hu not_active IP Right Cessation
- 1998-11-30 WO PCT/EP1998/007662 patent/WO1999029331A1/en not_active Ceased
- 1998-11-30 PT PT98959890T patent/PT1035859E/pt unknown
- 1998-11-30 EP EP98959890A patent/EP1035859B1/en not_active Expired - Lifetime
- 1998-11-30 KR KR1020007005420A patent/KR100567867B1/ko not_active Expired - Fee Related
- 1998-11-30 PL PL340884A patent/PL191023B1/pl not_active IP Right Cessation
- 1998-11-30 SI SI9830609T patent/SI1035859T1/xx unknown
- 1998-11-30 CA CA002312795A patent/CA2312795C/en not_active Expired - Fee Related
- 1998-11-30 SK SK827-2000A patent/SK284865B6/sk not_active IP Right Cessation
- 1998-11-30 ES ES98959890T patent/ES2214755T3/es not_active Expired - Lifetime
- 1998-11-30 JP JP2000524000A patent/JP4456267B2/ja not_active Expired - Fee Related
- 1998-11-30 AU AU15627/99A patent/AU743031B2/en not_active Ceased
- 1998-11-30 AT AT98959890T patent/ATE258802T1/de active
- 1998-11-30 DK DK98959890T patent/DK1035859T3/da active
- 1998-12-29 BR BRPI9805813-4A patent/BR9805813B1/pt not_active IP Right Cessation
2000
- 2000-05-31 US US09/580,906 patent/US6297218B1/en not_active Expired - Lifetime
- 2000-06-02 NO NO20002827A patent/NO324796B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
BR9805813B1 (pt)	2009-05-05
HUP0100522A2 (hu)	2001-12-28
WO1999029331A1 (en)	1999-06-17
RU2207866C2 (ru)	2003-07-10
DE69821524D1 (de)	2004-03-11
IT1296920B1 (it)	1999-08-03
ATE258802T1 (de)	2004-02-15
DK1035859T3 (da)	2004-05-17
BR9805813A (pt)	1999-12-14
AU1562799A (en)	1999-06-28
AU743031B2 (en)	2002-01-17
JP2001525370A (ja)	2001-12-11
CZ20002038A3 (cs)	2000-12-13
HK1033267A1 (en)	2001-08-24
JP4456267B2 (ja)	2010-04-28
NO20002827L (no)	2000-06-02
CZ299555B6 (cs)	2008-09-03
CN1126564C (zh)	2003-11-05
ITMI972690A1 (it)	1999-06-04
KR20010024654A (ko)	2001-03-26
HU228109B1 (en)	2012-11-28
HUP0100522A3 (en)	2002-04-29
US6297218B1 (en)	2001-10-02
CA2312795C (en)	2009-01-20
CN1280498A (zh)	2001-01-17
PL191023B1 (pl)	2006-03-31
EP1035859A1 (en)	2000-09-20
SI1035859T1 (en)	2004-04-30
CA2312795A1 (en)	1999-06-17
KR100567867B1 (ko)	2006-04-04
ES2214755T3 (es)	2004-09-16
DE69821524T2 (de)	2005-01-05
PL340884A1 (en)	2001-03-12
NO324796B1 (no)	2007-12-10
NO20002827D0 (no)	2000-06-02
SK8272000A3 (en)	2000-11-07
EP1035859B1 (en)	2004-02-04
PT1035859E (pt)	2004-05-31

Legal Events

Date	Code	Title	Description
2014-08-05	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20131130

Publication	Publication Date	Title
SK284865B6 (sk)	2006-01-05	Použitie fosfolipidových komplexov oligomérnych proantokyanidov extrahovaných z Vitis vinifera na prevenciu a liečenie aterosklerotických patologických ťažkostí
RU2272620C2 (ru)	2006-03-27	Способы снижения пролиферации клеток на основе (3r,4r)△8 - тетрагидроканнабинол-11-оновых кислот (кислот из конопли)
SK10802001A3 (sk)	2001-12-03	Esenciálne mastné kyseliny na prevenciu kardiovaskulárnych príhod
WO2011143587A1 (en)	2011-11-17	Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
CA2521149C (en)	2014-03-25	Annatto extract compositions, including geranyl geraniols and methods of use
AU763907B2 (en)	2003-08-07	Phospholipid complexes of proanthocyanidin A2 as antiatherosclerotic agents
EP0739629B1 (fr)	2003-09-24	Nouvelles associations comprenant du (-)hydroxycitrate et présentant notamment de nouvelles activités thérapeutiques
HK1033267B (en)	2004-07-16	The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents
Neri et al.	2019	EXPERIMENTAL STUDY ON VASOCONSTRICTION AND INFLAMMATION: ROLE OFLIPOXYGENASE PRODUCTS
RO128803A0 (ro)	2013-09-30	Compoziţie pentru tratamentul sau prevenirea dislipidemiilor